Abbott Earnings Reports

Abbott delivered solid Q3 2025 results with revenue of $11.37B and adjusted EPS of $1.30, driven by growth in Medical Devices and strong momentum in Diabetes Care.

Abbott delivered strong Q2 2025 results, posting solid revenue growth, double-digit EPS growth, and significant momentum in its medical devices segment, driven by products like FreeStyle Libre and structural heart devices.

Abbott delivered a solid Q1 2025 with 4.0% reported sales growth and adjusted EPS of $1.09. Net income rose to $1.33B, supported by strength in Diabetes Care and Structural Heart devices.

Abbott's Q4 2024 results showed strong momentum with sales growth and EPS growth reaching the highest of the year. The company achieved the upper end of its initial guidance ranges for 2024 and projects continued strong growth in 2025.

Abbott's Q3 2024 earnings showcased a robust performance, with sales of $10.6 billion driven by strong underlying base business performance. The company reported a GAAP diluted EPS of $0.94 and an adjusted diluted EPS of $1.21. Abbott has raised the midpoint of its full-year EPS guidance range.

Abbott reported strong Q2 2024 results, with sales reaching $10.4 billion. The company's performance was driven by its underlying base business, particularly Medical Devices, which experienced double-digit growth. Abbott raised its full-year EPS and narrowed its organic sales growth guidance.

Abbott reported a 2.2% increase in sales, driven by strong performance in Medical Devices and Established Pharmaceuticals. The company raised its full-year sales and EPS guidance.

Abbott's Q4 2023 earnings showcased a 1.5% increase in reported sales, with organic sales growth for the underlying base business increasing by 11.0%. The company issued full-year 2024 guidance for diluted EPS on a GAAP basis of $3.20 to $3.40 and full-year adjusted diluted EPS of $4.50 to $4.70, projecting organic sales growth, excluding COVID-19 testing-related sales, to be in the range of 8.0% to 10.0%.

Abbott's Q3 2023 earnings were driven by strong underlying base business performance, with sales of $10.1 billion. The company narrowed its full-year 2023 EPS guidance range and continues to project full-year 2023 organic sales growth, excluding COVID-19 testing-related sales, to be in the low double-digits.

Abbott's second-quarter 2023 results revealed a decrease in reported sales by 11.4 percent, attributed to an anticipated decline in COVID-19 testing-related sales. However, the underlying base business demonstrated strength, with organic sales growth of 11.5 percent, led by Medical Devices, Established Pharmaceuticals, and Nutrition. The company is strengthening its portfolio through new product approvals and expanded reimbursement coverage.

Abbott's Q1 2023 sales reached $9.7 billion, driven by strong underlying base business performance. The reported sales decreased by 18.1 percent due to an anticipated decline in COVID-19 testing-related sales compared to the previous year. The organic sales growth for the underlying base business was 10.0 percent, led by Medical Devices, Established Pharmaceuticals, and Nutrition.

Abbott's Q4 2022 sales reached $10.1 billion, but were negatively impacted by a decline in COVID-19 testing-related sales. The company's GAAP diluted EPS was $0.59, and adjusted diluted EPS was $1.03. Abbott issued full-year 2023 guidance for diluted EPS from continuing operations on a GAAP basis of $3.05 to $3.25 and full-year adjusted EPS from continuing operations of $4.30 to $4.50.

Abbott's Q3 2022 earnings showcased a mixed performance with a decrease in reported sales but an increase in organic sales. The company raised its full-year EPS guidance, driven by growth in U.S. Medical Devices and Established Pharmaceuticals, while navigating challenges in Nutrition and Diagnostics segments.

Abbott announced strong second-quarter results, with worldwide sales increasing by 10.1 percent on a reported basis and 14.3 percent on an organic basis. The company is raising its full-year EPS guidance.

Abbott's Q1 2022 sales reached $11.9 billion, a 13.8% increase, or 17.5% on an organic basis. Excluding COVID-19 testing-related sales, worldwide sales increased 3.9 percent on a reported basis and 7.7 percent on an organic basis. The company projects full-year 2022 diluted earnings per share under GAAP of at least $3.35 and adjusted diluted earnings per share of at least $4.70.

Abbott announced strong fourth-quarter and full-year 2021 financial results. The company's worldwide sales increased 7.2 percent on a reported basis and 7.7 percent on an organic basis. Abbott projects full-year 2022 diluted earnings per share from continuing operations under GAAP of at least $3.43.

Abbott announced strong growth overall and across all four of its major business areas in Q3 2021. The company is pleased with the continued advancements of its new product pipeline, including several recent launches in large, high-growth markets.

Abbott's Q2 2021 results revealed a robust performance, with worldwide sales reaching $10.2 billion, a 39.5% increase on a reported basis and 35.0% organically. Excluding COVID-19 testing-related sales, sales grew 11.3% organically compared to pre-pandemic levels in Q2 2019. The company's EPS guidance for 2021 is $2.75 to $2.95.

Abbott's first-quarter sales reached $10.5 billion, a 35.3% increase, driven by strong performance across all four major business segments. The company is particularly pleased with the momentum of recently launched products and forecasts over 35% EPS growth for the year.

Abbott's Q4 2020 results showed strong growth, with worldwide sales increasing by 28.7 percent on a reported basis and 28.4 percent on an organic basis. The company achieved double-digit EPS growth and is forecasting EPS growth of more than 35 percent in 2021.

Abbott announced strong Q3 2020 financial results, driven by innovation and delivery despite challenging conditions. The company's new product pipeline remained highly productive, positioning it well to finish the year with momentum.

Abbott's Q2 2020 worldwide sales reached $7.3 billion, a decrease of 8.2 percent on a reported basis but only a 5.4 percent decrease on an organic basis. The company's diversified business model and leadership in COVID-19 testing contributed to significant improvements in growth trends throughout the quarter.

Abbott's Q1 2020 worldwide sales reached $7.7 billion, a 2.5% increase on a reported basis and a 4.3% increase on an organic basis. The company launched three new COVID-19 tests and is suspending its previously announced annual guidance for 2020 due to uncertainties related to the pandemic.

Abbott's Q4 2019 sales increased by 7.1 percent on a reported basis and 8.5 percent on an organic basis. The company is entering 2020 with good momentum and targeting continued strong growth.